Takeda Pharmaceutical Company Limited is to invest €40m in a new facility at their Grange Castle site in Dublin, it was announced today.
Takeda is the largest pharmaceutical company in Japan and a Global industry leader. The company first set up operations in Ireland in 1997 manufacturing products for global markets. In 2002, Takeda chose Dublin as the location for its first active pharmaceutical ingredient (API) facility outside of Japan.
The investment by Takeda will expand their Grange Castle site’s existing footprint with the construction of a new standalone high containment production facility dedicated to manufacturing its oncology product NINLAROTM for global markets. The investment will create approximately 40 new jobs.
Welcoming the new investment by Takeda, Minister for Jobs, Enterprise and Innovation, Minister Mitchell O'Connor said, "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors."
She added, "Takeda's decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I'm delighted that this investment will bring a further 40 jobs to the company's existing Clondalkin facility."